AbbVie invests $380 million to build two new API manufacturing facilities in North Chicago while Bora Pharmaceuticals Co., Ltd. and GSK have renewed a five-year global manufacturing partnership.
Pharmaceutical Technology on MSN
AbbVie announces $380m investment in North Chicago API facilities
Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.
Feb 23 (Reuters) - AbbVie on Monday said it would invest $380 million to build two new active pharmaceutical ingredient ...
AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities at its current North Chicago, Illinois, campus. These ...
How integrated pharmaceutical manufacturing helps CDMOs simplify scale-up, reduce complexity, and move from raw materials to finished dosage forms faster.
MUSCAT, FEB 23As Oman advances its ambitions under Oman Vision 2040, the spotlight is increasingly shifting from mere ...
In this forward-looking whitepaper, Blue Mountain explores how agentic AI —autonomous, context-aware AI agents—could ...
Scinai Immunotherapeutics Ltd. ;("Scinai", or the "Company"), today announced that, following an additional review by the Israel Innovation Authority (IIA), its project to advance a robotic aseptic ...
JPLoft advances enterprise automation with intelligent AI agents that streamline operations, enhance decision-making, ...
The global market for N-TOPCon Cells was valued at USD 10020 Million in the year 2024 and is projected to reach a revised size of U ...
Pursuant to the Notification, the Company has 60 calendar days to submit to Nasdaq a plan to regain compliance from the date of receipt of the Notification and if the plan is accepted by Nasdaq, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results